Pharmaceutical Drug Development Services Market: By Molecule Type, By Phase, By Specialty Area and Region Forecast 2020-2031
Pharmaceutical Drug Development Services Market size was valued at US$ 18.6 billion in 2024 and is expected to reach US$ 46.8 billion by 2031, growing at a significant CAGR of 14.1% from 2025-2031. Owing to increasing stringent regulatory framework and cost of drug development for products coupled with focus of the oxytocic pharmaceuticals and biopharmaceutical companies on CROs and CDMOs to reduce the cost of the development of the product are the major factors that are driving the growth of the pharmaceutical drug development services market. Moreover, Identification of lead, drug discovery, clinical trial monitoring and regulatory compliance fuels the growth of the market over the forecast period. This report studies global pharmaceutical drug development services market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
Study Period
2025-2031Base Year
2024CAGR
14.1%Largest Market
Asia-PacificFastest Growing Market
North-America
The pharmaceutical and biopharmaceutical companies are focusing on the strategic collaborations with the drug development service providers to avoid the stringent regulatory policies and to reduce the cost of the drug development and this is the trend that was being observed in the market. For instance, in June 2018, Syneos Health and Elligo Health Research entered into a strategic collaboration to mobilize a system of accelerated research to reach real-world patients.
North America accounted for larger revenue share in global pharmaceutical drug development services market with significant CAGR owing to the presence of large number of prominent market players in the region and increasing adoption of eClinical solutions and rise in the use of interactive response technology in adaptive clinical trials. Asia Pacific region is expected to grow at highest CAGR owing to more number of CDMOs and CROs presence in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 18.6 billion |
|
Market Size in 2031 |
US$ 46.8 billion |
|
Market CAGR |
14.1% |
|
By Molecule Type |
|
|
By Phase |
|
|
By Specialty Area |
|
|
By End User |
|
Download Free Sample Report
Pharmaceutical Drug Development Services Market size was valued at US$ 18.6 billion in 2024 and is expected to reach US$ 46.8 billion by 2031, growing at a significant CAGR of 14.1% from 2025-2031.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Pharmaceutical Drug Development Services Market Introduction |
| 2.1. Global Pharmaceutical Drug Development Services Market – Taxonomy |
| 2.2. Global Pharmaceutical Drug Development Services Market – Definitions |
| 2.2.1. By Molecule |
| 2.2.2. By Phase |
| 2.2.3. By Specialty Type |
| 3. Global Pharmaceutical Drug Development Services Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Pharmaceutical Drug Development Services Market Dynamics – Factors Impact Analysis |
| 4. Global Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Pharmaceutical Drug Development Services Market Forecast, By Molecule, 2018 - 2022 and Forecast, 2023 - 2029 |
| 5.1. Biologic Solutions |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Small Molecule Solutions |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Biosimilar Development Solutions |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Pharmaceutical Drug Development Services Market Forecast, By Phase, 2018 - 2022 and Forecast, 2023 - 2029 |
| 6.1. Pre-Clinical |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Phase 1 |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Phase II |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Phase III |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global Pharmaceutical Drug Development Services Market Forecast, By Specialty Type, 2018 - 2022 and Forecast, 2023 - 2029 |
| 7.1. Cardiovascular |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Diabetes, Endocrinology, and Nephrology |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Immuno-Oncology |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Infectious Diseases |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Oncology |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Rare Diseases and Orphan Drugs |
| 7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Pediatrics |
| 7.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 7.8. Neuroscience |
| 7.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.8.3. Market Opportunity Analysis |
| 7.9. Others |
| 7.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.9.3. Market Opportunity Analysis |
| 8. Global Pharmaceutical Drug Development Services Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. The Middle East & Africa |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Product, By Application, By End User, and Region, 2023 - 2029 |
| 9. North America Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Biologic Solutions |
| 9.1.2. Small Molecule Solutions |
| 9.1.3. Biosimilar Development Solutions |
| 9.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Pre-Clinical |
| 9.2.2. Phase I |
| 9.2.3. Phase II |
| 9.2.4. Phase III |
| 9.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Cardiovascular |
| 9.3.2. Diabetes, Endocrinology, and Nephrology |
| 9.3.3. Immuno-Oncology |
| 9.3.4. Infectious Diseases |
| 9.3.5. Oncology |
| 9.3.6. Rare Diseases and Orphan Drugs |
| 9.3.7. Pediatrics |
| 9.3.8. Neuroscience |
| 9.3.9. Others |
| 9.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. U.S. |
| 9.4.2. Canada |
| 9.5. North America Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule Type, By Phase, By Specialty Type, and Country, 2023 - 2029 |
| 9.6. North America Pharmaceutical Drug Development Services Market Dynamics – Trends |
| 10. Europe Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 10.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Biologic Solutions |
| 10.1.2. Small Molecule Solutions |
| 10.1.3. Biosimilar Development Solutions |
| 10.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Pre-Clinical |
| 10.2.2. Phase I |
| 10.2.3. Phase II |
| 10.2.4. Phase III |
| 10.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Cardiovascular |
| 10.3.2. Diabetes, Endocrinology, and Nephrology |
| 10.3.3. Immuno-Oncology |
| 10.3.4. Infectious Diseases |
| 10.3.5. Oncology |
| 10.3.6. Rare Diseases and Orphan Drugs |
| 10.3.7. Pediatrics |
| 10.3.8. Neuroscience |
| 10.3.9. Others |
| 10.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. U.K. |
| 10.4.2. Germany |
| 10.4.3. France |
| 10.4.4. Italy |
| 10.4.5. Spain |
| 10.4.6. Russia |
| 10.4.7. Rest of Europe |
| 10.5. Europe Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029 |
| 10.6. Europe Pharmaceutical Drug Development Services Market Dynamics – Trends |
| 11. Asia Pacific Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 11.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Biologic Solutions |
| 11.1.2. Small Molecule Solutions |
| 11.1.3. Biosimilar Development Solutions |
| 11.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Pre-Clinical |
| 11.2.2. Phase I |
| 11.2.3. Phase II |
| 11.2.4. Phase III |
| 11.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Cardiovascular |
| 11.3.2. Diabetes, Endocrinology, and Nephrology |
| 11.3.3. Immuno-Oncology |
| 11.3.4. Infectious Diseases |
| 11.3.5. Oncology |
| 11.3.6. Rare Diseases and Orphan Drugs |
| 11.3.7. Pediatrics |
| 11.3.8. Neuroscience |
| 11.3.9. Others |
| 11.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. China |
| 11.4.2. Japan |
| 11.4.3. India |
| 11.4.4. ASEAN Counties |
| 11.4.5. Philippines |
| 11.4.6. Rest of Asia Pacific |
| 11.5. Asia Pacific Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029 |
| 11.6. Asia Pacific Pharmaceutical Drug Development Services Market Dynamics – Trends |
| 12. Latin America Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 12.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Biologic Solutions |
| 12.1.2. Small Molecule Solutions |
| 12.1.3. Biosimilar Development Solutions |
| 12.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Pre-Clinical |
| 12.2.2. Phase I |
| 12.2.3. Phase II |
| 12.2.4. Phase III |
| 12.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Cardiovascular |
| 12.3.2. Diabetes, Endocrinology, and Nephrology |
| 12.3.3. Immuno-Oncology |
| 12.3.4. Infectious Diseases |
| 12.3.5. Oncology |
| 12.3.6. Rare Diseases and Orphan Drugs |
| 12.3.7. Pediatrics |
| 12.3.8. Neuroscience |
| 12.3.9. Others |
| 12.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Mexico |
| 12.4.2. Brazil |
| 12.4.3. Argentina |
| 12.4.4. Chile |
| 12.4.5. Rest of Latin America |
| 12.5. Latin America Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029 |
| 12.6. Latin America Pharmaceutical Drug Development Services Market Dynamics – Trends |
| 13. Middle East and Africa Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 13.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Biologic Solutions |
| 13.1.2. Small Molecule Solutions |
| 13.1.3. Biosimilar Development Solutions |
| 13.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Pre-Clinical |
| 13.2.2. Phase I |
| 13.2.3. Phase II |
| 13.2.4. Phase III |
| 13.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Cardiovascular |
| 13.3.2. Diabetes, Endocrinology, and Nephrology |
| 13.3.3. Immuno-Oncology |
| 13.3.4. Infectious Diseases |
| 13.3.5. Oncology |
| 13.3.6. Rare Diseases and Orphan Drugs |
| 13.3.7. Pediatrics |
| 13.3.8. Neuroscience |
| 13.3.9. Others |
| 13.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. GCC Countries |
| 13.4.2. South Africa |
| 13.4.3. Saudi Arabia |
| 13.4.4. Turkey |
| 13.4.5. Rest of MEA |
| 13.5. Middle East & Africa Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029 |
| 13.6. Middle East & Africa Pharmaceutical Drug Development Services Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Market Player – Competition Matrix (By Tier and Size of Companies) |
| 14.2. Company Profiles (Includes Company Overview, Business Description, Financials, SWOT Analysis, and Strategic Developments) |
| 15. Assumptions and Acronyms Used |
| 16. Research Methodology |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
